卵巢癌是常见的妇女恶性肿瘤,在女性生殖器恶性肿瘤中,发病率仅次于宫颈癌和宫体癌居第三位,但死亡率却高于后两者之和。由于缺乏早期诊断方法,约有2/3病人,在初次手术时已至晚期(Ⅲ和Ⅳ期),目前的治疗方法还很不理想,过去的30年中,总的五年生存率变化不大,仅在25～33%之间。目前手术仍是治疗卵巢癌的首选方法,近10余年来由于分子生物学和细胞增殖动力学的迅猛发展,以及抗癌药物的不断更新,使化疗有了很大的进展,化学疗法已成为治疗卵巢癌的重要辅助手段。在治疗的过程中 Ovarian cancer is a common malignant tumor in women. In female genital malignancies, the incidence of ovarian cancer ranks the third only after cervical cancer and uterine cancer, but the mortality rate is higher than the sum of the latter two. Due to a lack of early diagnosis, approximately two-thirds of patients have advanced to advanced stage (stage III and IV) and the current treatment is far from ideal. In the past 30 years, the overall five-year survival rate did not change Large, only between 25 ~ 33%. Currently surgery is still the preferred method of treatment of ovarian cancer, the past 10 years due to the rapid development of molecular biology and cell proliferation kinetics, as well as the continuous update of anti-cancer drugs, chemotherapy has made great progress, chemotherapy has become a treatment Ovarian cancer is an important aid. In the process of treatment